Indaptus Therapeutics Inc (INDP) Stock AnalysisINDPIndaptus Therapeutics Inc

Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company, which specializes in cancer and viral infection treatments. The Company’s approach is based on the hypothesis that activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Its technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The Company's lead clinical candidate is Decoy20. Its Decoy product candidates have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Indaptus Therapeutics Inc is not a strong buy at this moment due to its recent performance and financial instability. The current price is $2.63, with a 1-year change of -32.56%, indicating a significant decline over the past year. Although the stock has seen a recent 5-day change of +4.78%, the overall trend remains negative. The company has a high price-to-book ratio of 33.39, suggesting it may be overvalued relative to its equity. The main risk is the negative earnings per share (EPS) of -0.02 reported in the last quarter, which reflects ongoing losses and financial challenges.